Cancer research meets evolutionary biology

Evolutionary Applications

Volumn 2, Issue 1, 2009, Pages 62-70

  Pepper, John W ^a,b   Findlay, C Scott ^c,d   Kassen, Rees ^c,e   Spencer, Sabrina L ^f   Maley, Carlo C ^g  

^a University of Arizona   (United States)

^b SANTA FE INSTITUTE   (United States)

^c UNIVERSITY OF OTTAWA   (Canada)

^d OTTAWA REGIONAL CANCER CENTRE   (Canada)

^e UNIVERSITY OF OTTAWA   (Canada)

^f Massachusetts Institute of Technology Cambridge   (United States)

^g WISTAR INSTITUTE   (United States)

Author keywords

Acquired drug resistance; Cancer progression; Drug development; Natural selection; Neoplasms; Somatic evolution; Stem cells; Transdisciplinary research

Indexed keywords

EID: 70350336005     PISSN: 17524563     EISSN: 17524571     Source Type: Journal    
DOI: 10.1111/j.1752-4571.2008.00063.x     Document Type: Article

References (77)

1. Adams, J. M., and A. Strasser. 2008. Is tumor growth sustained by rare cancer stem cells or dominant clones? Cancer Research 68:4018-4021.
2. Alain, T., M. Kim, R. N. Johnston, S. Urbanski, A. E. Kossakowska, P. A. Forsyth, and P. W. Lee. 2006. The oncolytic effect in vivo of reovirus on tumour cells that have survived reovirus cell killing in vitro. British Journal of Cancer 95:1020-1027.
3. Boehm, T., J. Folkman, T. Browder, and M. S. O'Reilly. 1997. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390:404-407.
4. Bursch, W., A. Ellinger, H. Kienzl, L. Torok, S. Pandey, M. Sikorska, R. Walker et al. 1996. Active cell death induced by the anti-estrogens tamoxifen and ICI 164 384 in human mammary carcinoma cells (MCF-7) in culture: the role of autophagy. Carcinogenesis 17:1595-1607.
5. Cairns, J. 1975. Mutation selection and the natural history of cancer. Nature 255:197-200.
6. Campbell, L. L., and K. Polyak. 2007. Breast tumor heterogeneity: cancer stem cells or clonal evolution? Cell Cycle 6:2332-2338. (Pubitemid 350058682)
7. Carman, M. D., J. H. Schornagel, R. S. Rivest, S. Srimatkandada, C. S. Portlock, T. Duffy, and J. R. Bertino. 1984. Resistance to methotrexate due to gene amplification in a patient with acute leukemia. Journal of Clinical Oncology 2:16-20.
8. Carrick, S., S. Parker, N. Wilcken, D. Ghersi, M. Marzo, and J. Simes. 2005. Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database of Systematic Reviews:CD003372.
9. Cho, R. W., and M. F. Clarke. 2008. Recent advances in cancer stem cells. Current Opinion in Genetics and Development 18:48-53.
10. Corley, D. A., K. Kerlikowske, R. Verma, and P. Buffler. 2003. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterol- ogy 124:47-56.
11. Costello, R. T., F. Mallet, B. Gaugler, D. Sainty, C. Arnoulet, J. A. Gastaut, and D. Olive. 2000. Human acute myeloid leukemia CD34 + /CD38-progenitor cells have decreased sensitivity to chemotherapy and Fas-induced apoptosis, reduced immunogenicity, and impaired dendritic cell transformation capacities. Cancer Research 60:4403-4411.
12. Crespi, B., and K. Summers. 2005. Evolutionary biology of cancer. Trends in Ecology and Evolution 20:545-552.
13. Curt, G. A., D. N. Carney, K. H. Cowan, J. Jolivet, B. D. Bailey, J. C. Drake, K. S. Chien Song et al. 1983. Unstable methotrexate resistance in human small-cell carcinoma associated with double minute chromosomes. New England Journal of Medicine 308:199-202.
14. Dang, L. H., C. Bettegowda, D. L. Huso, K. W. Kinzler, and B. Vogelstein. 2001. Combination bacteriolytic therapy for the treatment of experimental tumors. Proceedings of the National Academy of Science of the United State of America 98:15155-15160.
15. Davis, J. J., and B. Fang. 2005. Oncolytic virotherapy for cancer treatment: challenges and solutions. The Journal of Gene Medicine 7:1380-1389.
16. Dean, M., T. Fojo, and S. Bates. 2005. Tumour stem cells and drug resistance. Nature Reviews. Cancer 5:275-284.
17. Delbaldo, C., S. Michiels, N. Syz, J. C. Soria, T. Le Chevalier, and J. P. Pignon. 2004. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. The Journal of the American Medical Association 292:470-484.
18. Dobrikova, E. Y., T. Broadt, J. Poiley-Nelson, X. Yang, G. Soman, S. Giardina, R. Harris et al. 2008. Recombinant oncolytic poliovirus eliminates glioma in vivo without genetic adaptation to a pathogenic phenotype. Molecular Therapy 16:1865-1872.
19. Dowsett, M., N. J. Bundred, A. Decensi, R. C. Sainsbury, Y. Lu, M. J. Hills, F. J. Cohen et al. 2001. Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double-blind, placebo-controlled, randomized clinical trial in postmeno-pausal patients. Cancer Epidemiology, Biomarkers and Prevention 10:961-966.
20. Engelman, J. A., K. Zejnullahu, T. Mitsudomi, Y. Song, C. Hyland, J. O. Park, N. Lindeman et al. 2007. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039-1043.
21. Espey, D. K., X. C. Wu, J. Swan, C. Wiggins, M. A. Jim, E. Ward, P. A. Wingo et al. 2007. Annual report to the nation on the status of cancer, 1975-2004, featuring cancer in American Indians and Alaska Natives. Cancer 110:2119-2152.
22. Etzioni, R., N. Urban, S. Ramsey, M. McIntosh, S. Schwartz, B. J. Reid, J. P. Radich et al. 2003. The case for early detection. Nature Reviews Cancer 3:1-10.
23. Ewald, P. W. 1999. Using evolution as a tool for controlling infectious diseases. In W. R. Trevathan, E. O. Smith, and J. J. McKenna, eds. Evolutionary Medicine, pp. 245-270. Oxford University Press, Oxford.
24. Oxford University Press, Oxford. Falconer, D. S., and T. F. C. Mackay. 1996. Introduction to Quantitative Genetics. Longmans Green, Harlow, Essex, UK.
25. Felsenstein, J.. 1985. Phylogenies and the comparative method. American Naturalist 125:1-15.
26. Frank, S. A., and M. A. Nowak. 2004. Problems of somatic mutation and cancer. Bioessays 26:291-299.
27. Frumkin, D., A. Wasserstrom, S. Itzkovitz, T. Stern, A. Harme-lin, R. Eilam, G. Rechavi et al. 2008. Cell lineage analysis of a mouse tumor. Cancer Research 68:5924-5931.
28. Galipeau, P. C., X. Li, P. L. Blount, C. C. Maley, C. A. Sanchez, R. D. Odze, K. Ayub et al. 2007. NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Medicine 4:e67.
29. Gorre, M. E., M. Mohammed, K. Ellwood, N. Hsu, R. Paquette, P. N. Rao, and C. L. Sawyers. 2001. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293:876-880.
30. Gottesman, M. M., T. Fojo, and S. E. Bates. 2002. Multidrug resistance in cancer: role of ATP-dependent transporters. Nature Reviews Cancer 2:48-58.
31. Greaves, M. 2007. Darwinian medicine: a case for cancer. Nature Reviews Cancer 7:213-221.
32. Heng, H. H. 2007. Cancer genome sequencing: the challenges ahead. Bioessays 29:783-794.
33. Hill, R. P. 2006. Identifying cancer stem cells in solid tumors: case not proven. Cancer Research 66:1891-1895; discussion 1890.
34. Hope, K. J., L. Jin, and J. E. Dick. 2004. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nature Immunology 5:738-743.
35. Horns, R. C. Jr, W. J. Dower, and R. T. Schimke. 1984. Gene amplification in a leukemic patient treated with methotrexate. Journal of Clinical Oncology 2:2-7.
36. Kassen, R., and T. Bataillon. 2006. Distribution of fitness effects among beneficial mutations before selection in experimental populations of bacteria. Nature Genetics 38:484-488.
37. Keller, L. K.. 1999. Levels of Selection in Evolution. Princeton University Press, Princeton, NJ.
38. Kobayashi, S., T. J. Boggon, T. Dayaram, P. A. Janne, O. Kocher, M. Meyerson, B. E. Johnson et al. 2005. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. New England Journal of Medicine 352:786-792. (Pubitemid 40271173)
39. Leroi, A. M., V. Koufopanou, and A. Burt. 2003. Cancer selection. Nature Reviews Cancer 3:226-231.
40. Levin, B. R., and J. J. Bull. 2004. Population and evolutionary dynamics of phage therapy. Nature Reviews Microbiology 2:166-173.
41. Levin, B. R., M. Lipsitch, and S. Bonhoeffer. 1999. Population biology, evolution, and infectious disease: convergence and synthesis. Science 283:806-809.
42. Maley, C. C., and B. J. Reid. 2005. Natural selection in neo- plastic progression of Barrett's esophagus. Seminars in Cancer Biology 15:474-483.
43. Maley, C. C., P. C. Galipeau, X. Li, C. A. Sanchez, T. G. Paulson, P. L. Blount, and B. J. Reid. 2004a. The combination of genetic instability and clonal expansion predicts progression to esophageal adenocarcinoma. Cancer Research 64:7629-7633.
44. Maley, C. C., P. C. Galipeau, X. Li, C. A. Sanchez, T. G. Paulson, and B. J. Reid. 2004b. Selectively advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett's esophagus. Cancer Research 64:3414-3427.
45. Maley, C. C., B. J. Reid, and S. Forrest. 2004c. Cancer prevention strategies that address the evolutionary dynamics of neoplastic cells: simulating benign cell boosters and selection for chemosensitivity. Cancer Epidemiology, Biomarkers and Prevention 13:1375-1384.
46. Maley, C. C., P. C. Galipeau, J. C. Finley, V. J. Wongsurawat, X. Li, C. A. Sanchez, T. G. Paulson et al. 2006. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nature Genetics 38:468-473.
47. Mandlekar, S., and A. N. Kong. 2001. Mechanisms of tamoxifen-induced apoptosis. Apoptosis 6:469-477.
48. McBride, S. M. 2008. Natural selection's challenge to the cancer stem cell hypothesis. Medical Hypotheses 71:471-472.
49. Merlo, L. M., J. W. Pepper, B. J. Reid, and C. C. Maley. 2006. Cancer as an evolutionary and ecological process. Nature Reviews Cancer 6:924-935.
50. Michor, F., Y. Iwasa, and M. A. Nowak. 2004. Dynamics of cancer progression. Nature Reviews Cancer 4:197-205.
51. Moscow, J., C. S. Morrow, and C. H. Cowan. 2003. Drug resistance and its clinical circumvention. In D. W. Kufe, J. F. Holland, and E. Frei, eds. Cancer Medicine. pp. 711-725. Ont., B. C. Decker, Hamilton.
52. Mullighan, C. G., L. A. Phillips, X. Su, J. Ma, C. B. Miller, S. A. Shurtleff, and J. R. Downing. 2008. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 322:1377-1380.
53. Nowell, P. C. 1976. The clonal evolution of tumor cell populations. Science 194:23-28.
54. O'Connor, R., M. Clynes, P. Dowling, N. O'Donovan, and L. O'Driscoll. 2007. Drug resistance in cancer - searching for mechanisms, markers and therapeutic agents. Expert Opinion on Drug Metabolism & Toxicology 3:805-817.
55. Okasha, S. 2006. Evolution and the Levels of Selection. Clarendon Press, Oxford.
56. Orr, H. A.. 2005. The genetic theory of adaptation: a brief history. Nature Reviews Genetics 6:119-127.
57. Paulson, T. G., L. Xu, C. Sanchez, P. L. Blount, K. Ayub, R. D. Odze, and B. J. Reid. 2006. Neosquamous epithelium does not typically arise from Barrett's epithelium. Clinical Cancer Research 12:1701-1706.
58. Pepper, J. W. 2008a. Defeating pathogen drug resistance: guidance from evolutionary theory. Evolution 62:3185-3191.
59. Pepper, J. W. 2008b. Integrating evolutionary biology into cancer biology. http://www.santafe.edu/events/workshops/index.php/Integrating- Evolutionary-Theory-into-Cancer-Biology.
60. Pepper, J. W., K. Sprouffske, and C. C. Maley. 2007. Animal Cell Differentiation Patterns Suppress Somatic Evolution. PLoS Computational Biology 3:e250.
61. Polyak, K. 2007. Breast cancer stem cells: a case of mistaken identity? Stem Cell Reviews 3:107-109. (Pubitemid 350129711)
62. Robertson, J. F. 2004. Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective. Cancer Treatment Reviews 30:695-706.
63. Roche-Lestienne, C., and C. Preudhomme. 2003. Mutations in the ABL kinase domain pre-exist the onset of imatinib treatment. Seminars in Hematology 40:80-82.
64. Rowe-Magnus, D. A., and D. Mazel. 2006. The Evolution of Antibiotic Resistance. In H. S. Seifert, and V. J. Dirita, eds. Evolution of Microbial Pathogens, pp. 221-241. ASM Press, Washington, D.C.
65. Shah, N. P., B. J. Skaggs, S. Branford, T. P. Hughes, J. M. Nicoll, R. L. Paquette, and C. L. Sawyers. 2007. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. Journal of Clinical Investigation 117:2562-2569.
66. Shibata, D. 2008. Stem cells as common ancestors in a colorectal cancer ancestral tree. Current Opinion in Gastroenterology 24:59-63.
67. Shipitsin, M., L. L. Campbell, P. Argani, S. Weremowicz, N. Bloushtain-Qimron, J. Yao, T. Nikolskaya et al. 2007. Molecular definition of breast tumor heterogeneity. CancerCell 11:259-273
68. tearns, S. C., and J. C. Koella. 2008. Evolution in Health and Disease. Oxford University Press, Oxford.
69. Taplin, M. E., G. J. Bubley, Y. J. Ko, E. J. Small, M. Upton, B. Rajeshkumar, and S. P. Balk. 1999. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Research 59:2511-2515.
70. Trent, J. M., R. N. Buick, S. Olson, R. C. Horns Jr, and R. T. Schimke. 1984. Cytologic evidence for gene amplification in methotrexate-resistant cells obtained from a patient with ovarian adenocarcinoma. Journal of Clinical Oncology 2:8-15.
71. Vaughan, T. L., L. M. Dong, P. L. Blount, K. Ayub, R. D. Odze, C. A. Sanchez, P. S. Rabinovitch et al. 2005. Non- steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study. The Lancet Oncology 6:945-952.
72. Vincent, T. L., and J. S. Brown. 2005. Evolutionary Game Theory. Cambridge University Press, Cambridge.
73. Vincent, T. L. and R. A. Gatenby 2008. An evolutionary model for initiation, promotion, and progression in carcinogenesis. International Journal of Oncology 31(4):729-737.
74. Visakorpi, T., E. Hyytinen, P. Koivisto, M. Tanner, R. Keinanen, C. Palmberg, A. Palotie et al. 1995. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nature Genetics 9:401-406.
75. Visvader, J. E., and G. J. Lindeman. 2008. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nature Review Cancer 8:755-768.
76. Wang, J. C. 2007. Evaluating therapeutic efficacy against cancer stem cells: new challenges posed by a new paradigm. Cell Stem Cell 1:497-501.
77. Wang, T. L., L. A. Diaz Jr, K. Romans, A. Bardelli, S. Saha, G. Galizia, M. Choti et al. 2004. Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. Proceedings of the National Academy of Sciences of the United States of America 101:3089-3094.